Background Psoriasis is recognized as a refractory skin disease in the modern world. There are no safe and effective pharmacological treatments with few adverse effects for psoriasis. The objective of this study was to identify potential therapeutic targets for psoriasis through the integration of diverse datasets. Methods We integrated drug-available genomic data, human blood cis-eQTL/Cis-pQTL data, skin tissue cis-eQTL data, and psoriasis GWAS aggregated data, and used drug target Mendelian randomization, Steiger filter analysis, and colocalization analysis to verify the causal relationship between psoriasis and drug target genes. In addition, we perform PH-MR analyses to determine the safety of drug target genes at the genetic level. Results MR analysis identified seven drug genes that may be associated with psoriasis. All of these genes were further confirmed by Bayesian co-localization analysis. (PPH4 > 80%). The up-regulation of PSMB9 expression was associated with a lower risk of psoriasis in the blood eQTL dataset (HR:0.827, 95% CL: 0.780-0.877, P=2.491108e-10), blood pQTL dataset (HR:0.071, 95% CL: 0.036-0.141, P=3.521467e-14) and skin eQTL dataset (HR:0.764, 95% CL: 0.701-0.833, P=9.425763e-10).Increased TNF transcription levels may increase the risk of psoriasis in the blood pQTL (HR:2.590, 95%CL: 1.123-5.976, P=2.561598e-02) /eQTL (HR:1.338, 95%CL: 1.213-1.475, P=5.082644e-09). MICA, HSPA1L, AGER, COL11A2 and FOLH1 were verified in skin eQTL dataset and blood pQTL dataset. Increased transcription levels of FOLH1 may reduce the risk of psoriasis in skin eQTL dataset (HR:0.901, 95%CL: 0.849-0.956, P=5.672095e-04) and blood pQTL dataset (HR:0.813, 95%CL: 0.671-0.987, P=3.4118311e-02); Increased transcription levels of MICA may reduce the risk of psoriasis in skin eQTL dataset (HR:0.787, 95%CL: 0.691-0.896, P=1.048889e-02) and blood pQTL dataset (HR:0.864, 95%CL: 1.048889E-02). 0.762-0.981, P=2.360710e-14). Conclusions: Our study suggests that PSMB9, MICA, HSPA1L, AGER, COL11A2 and FOLH1 may be promising targets for the treatment of psoriasis. However, the role of Artenimol in psoriasis needs to be further verified.